Journal article
Bortezomib, Lenalidomide and Dexamethasone (VRD) Followed By Autologous Stem Cell Transplant for Newly Diagnosed Multiple Myeloma; The Mayo Clinic Experience
Abstract
Abstract
We retrospectively reviewed all patients receiving bortezomib, lenalidomide and dexamethasone induction followed by autologous stem cell transplantation (ASCT) within 12 months of diagnosis for multiple myeloma at the Mayo Clinic.
Authors
Sidiqi MH; Aljama MA; Dispenzieri A; Muchtar E; Buadi FK; Warsame R; Lacy MQ; Dingli D; Leung N; Gonsalves WI
Journal
Blood, Vol. 132, No. Supplement 1,
Publisher
American Society of Hematology
Publication Date
November 29, 2018
DOI
10.1182/blood-2018-99-111147
ISSN
0006-4971